



Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference

December 1, 2014

San Diego, Calif., Dec 1, 2014 – Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that Joseph E. Payne, President & CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference being held on December 2-3 at New York Palace hotel in NY. The company presentation will take place on December 2nd, at 3:30 PM EST.

"We are pleased to provide a corporate overview highlighting the significant progress we have made with our leading UNA Oligomer™ chemistry and LUNAR™ delivery technologies, as well as our growing pipeline of RNA medicines," said Joseph E. Payne, President & CEO of Arcturus Therapeutics.

About Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart. TTR-mediated cardiomyopathy (FAC) affects approximately

40,000 people with the mean survival of ~2.5 years. TTR-mediated polyneuropathy (FAP) affects at least 10,000 people. There is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.

About Arcturus Therapeutics, Inc.

Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR™, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense RNA, and microRNA oligotherapeutics. The company's UNA Oligomer™ chemistry technology and patent portfolio (34 patents, USPTO granted) enables the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.

#